EMD Serono Research & Development Institute, Inc.
Clinical trials sponsored by EMD Serono Research & Development Institute, Inc., explained in plain language.
A research and development arm of Merck KGaA, focusing on biopharmaceutical innovations.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced colorectal cancer: first human trial launches Results expected Oct 2026 (estimated)
- New drug combo shows promise for Hard-to-Treat cancers Results expected Nov 2026 (estimated)
- New drug combo targets Hard-to-Treat cancers in early trial Results expected Feb 2027 (estimated)
- New cancer drug M3554 targets tough tumors in first human trial Results expected Apr 2027 (estimated)